A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency

Inclusion Criteria:

1. Investigator-determined GHD diagnosis prior to the historical initiation of daily hGH
therapy.

2. 6 months to 17 years old, inclusive, at Visit 1

1. If 3 to 17 years old, are taking daily hGH at a dose of ≥ 0.20 mg hGH/kg/week for
at least 13 weeks but no more than 130 weeks prior to Visit 1

2. If ≥ 6 months but < 3 years old, are either hGH treatment-naïve or are taking
daily hGH at a dose of ≥ 0.20mg hGH/kg/week for no more than 130 weeks prior to
Visit 1

3. Tanner stage < 5 at Visit 1

4. Open epiphyses (bone age ≤14.0 years for females or ≤16.0 years for males)

5. Written, signed, informed consent of the parent or legal guardian of the subject and
written assent of the subject as required by the IRB/HREC/IEC

Exclusion Criteria:

1. Weight of < 5.5 kg or > 80 kg at Visit 1

2. Females of child-bearing potential

3. History of malignant disease

4. Any clinically significant abnormality likely to affect growth or the ability to
evaluate growth (eg, chronic diseases or conditions such as renal insufficiency,
spinal cord irradiation, hypothyroidism, active celiac disease, malnutrition or
psychosocial dwarfism)

5. Poorly-controlled diabetes mellitus (HbA1c >8.0%) or diabetic complications

6. Known neutralizing antibodies against hGH

7. Major medical conditions, unless approved by Medical Monitor

8. Pregnancy

9. Presence of contraindications to hGH treatment

10. Likely to be non-compliant with respect to trial conduct (in regards to the subject
and/or the parent/legal guardian/caregiver)

11. Participation in any other trial of an investigational agent within 30 days prior to
Visit 1

12. Prior exposure to investigational hGH